[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100089330":3},{"organization":4,"armGroups":7,"interventions":29,"overallOfficials":46,"centralContacts":34,"locations":70,"responsibleParty":83,"collaborators":34,"id":85,"slug":86,"hasResults":87,"nctId":88,"briefTitle":89,"officialTitle":89,"acronym":34,"eligibilityCriteria":90,"healthyVolunteers":87,"sex":91,"minAge":92,"maxAge":93,"enrollmentInfo":94,"targetDuration":34,"studyType":97,"phases":98,"briefSummary":100,"conditions":101,"keywords":103,"overallStatus":105,"whyStopped":34,"lastUpdateSubmitDate":106,"lastUpdatePostDateStruct":107,"startDateStruct":110,"completionDateStruct":112,"leadSponsor":114,"locationsCount":115},{"fullName":5,"class":6},"Nantes University Hospital","OTHER",[8,17,21,25],{"label":9,"type":10,"description":11,"interventionNames":12},"1","EXPERIMENTAL","Non diabetic non dyslipidemic patient",[13,14,15,16],"Procedure: biopsy of muscle, of liver, and of adipose tissue","Procedure: clamp euglycemic - hyperglycemic","Behavioral: diet","Other: biopsies for biological and genetic analyses",{"label":18,"type":10,"description":19,"interventionNames":20},"2","Patient with metabolic syndrome",[13,14,15,16],{"label":22,"type":10,"description":23,"interventionNames":24},"3","Patients with type II diabetes",[13,14,15,16],{"label":26,"type":10,"description":27,"interventionNames":28},"4","Patient with a single lipidic anomaly",[13,14,15,16],[30,35,39,43],{"type":31,"name":32,"description":32,"armGroupLabels":33,"otherNames":34},"PROCEDURE","biopsy of muscle, of liver, and of adipose tissue",[9,18,22,26],null,{"type":31,"name":36,"description":37,"armGroupLabels":38,"otherNames":34},"clamp euglycemic - hyperglycemic","clamp euglycemic-hyperglycemic",[9,18,22,26],{"type":40,"name":41,"description":41,"armGroupLabels":42,"otherNames":34},"BEHAVIORAL","diet",[9,18,22,26],{"type":6,"name":44,"description":44,"armGroupLabels":45,"otherNames":34},"biopsies for biological and genetic analyses",[9,18,22,26],[47,50,52,54,56,59,61,64,67],{"name":48,"affiliation":5,"role":49},"Bertrand Cariou, MD","PRINCIPAL_INVESTIGATOR",{"name":51,"affiliation":5,"role":49},"Michel Krempf, MD",{"name":53,"affiliation":5,"role":49},"Yassine Zaïr, MD",{"name":55,"affiliation":5,"role":49},"Eric Letessier, MD",{"name":57,"affiliation":58,"role":49},"Charles Couet, MD","CHU de Tours",{"name":60,"affiliation":58,"role":49},"Noël Huten, MD",{"name":62,"affiliation":63,"role":49},"Philippe Topart, MD","CHU de Brest",{"name":65,"affiliation":66,"role":49},"David Lechaux, MD","CHU de St Brieuc",{"name":68,"affiliation":69,"role":49},"Jean-Pierre Faure, MD","Poitiers University Hospital",[71],{"facility":72,"status":34,"city":73,"state":34,"zip":74,"country":75,"countryCode":76,"cosmosGeoPoint":77,"geoPoint":82,"contacts":34},"CHU de Nantes","Nantes","44093","France","FR",{"type":78,"coordinates":79},"Point",[80,81],-1.55336,47.21725,{"lat":81,"lon":80},{"type":84,"investigatorFullName":34,"investigatorTitle":34,"investigatorAffiliation":34,"oldNameTitle":34,"oldOrganization":34},"SPONSOR","100089330","study-of-the-role-of-pcsk9-and-fxr-in-the-physiopathology-of-the-joint-dyslipidemia-associated-to-the-human-immunoresistance-100089330",false,"NCT00422006","Study of the Role of PCSK9 and FXR in the Physiopathology of the Joint Dyslipidemia Associated to the Human Immunoresistance","Inclusion Criteria:\n\n* corporal mass index \\> 40 kg\u002Fm² or \\> 35 kg\u002Fm² associated to a co-morbidity resistant to a diet\n* bariatric surgery planned\n* no lipid-lowering drugs during 4 weeks before surgery\n* no treatment by metformin during 4 weeks before surgery\n* no treatment by glitazones during 8 weeks before surgery\n* age of the patient between 18 and 65 years\n* consent form signed\n* patient with social insurance\n\nExclusion Criteria:\n\n* age inferior to 18 years\n* women pregnant\n* coagulation troubles\n* surgery contraindicated\n* Chronic hepatitis B or C active\n* VIH infected\n* other chronic hepatic disease\n* patient with dyslipidemia under lipid-lowering drugs in secondary prevention of a cardiovascular pathology\n* Type 2 diabetes under insulinosensitivator treatments","ALL","18 Years","65 Years",{"count":95,"type":96},111,"ACTUAL","INTERVENTIONAL",[99],"NA","Experimental results are strongly suggesting that PCSK9 and FXR could occur in the physiopathology of human joined dyslipidemia. But no data in the literature can validate the potential role of these two genes in the lipidic and glucidic metabolism control in physiopathological situations. This protocol is based on the hypothesis that the expression levels of PCSK 9 and FXR are modified for some patients suffering from insulin resistance and dyslipidemia.",[102],"Obesity",[104],"bariatric surgery planned","COMPLETED","2014-04-02",{"date":108,"type":109},"2014-04-03","ESTIMATED",{"date":111,"type":34},"2008-02",{"date":113,"type":96},"2013-11",{"name":5,"class":6},1]